Matches in Nanopublications for { ?s ?p "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." ?g. }
Showing items 1 to 14 of
14
with 100 items per page.
- _4 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _3 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _6 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _3 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _3 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _3 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _4 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _3 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _5 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _4 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _3 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _5 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _4 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.
- _6 value "In the present study, we examined the effects of rosiglitazone (RGZ) (rosaglitazone is a Pparg agonist) on insulin release and synthesis in pancreatic beta-cell (INS-1). Insulin release and synthesis were stimulated by treatment with RGZ for 24h. RGZ upregulated the expressions of GLUT-2 and glucokinase (GCK). Moreover, it was found that RGZ increased the expression of BETA2/NeuroD gene which could regulate insulin gene expression." provenance.